Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Skin Neoplasms 1 Recurrence 1 Neoplasms 1 Melanoma 1

Interventions

pembrolizumab 40 Nivolumab 18 trametinib 13 Cyclophosphamide 13 dabrafenib 11 Vemurafenib 10 Interleukin-2 10 Ipilimumab 9 fludarabine 7 Docetaxel 7 fludarabine phosphate 6 cemiplimab 6 Paclitaxel 6 Cisplatin 6 Carboplatin 6 atezolizumab 5 Radiotherapy 5 Drug Therapy 5 Dacarbazine 5 Blood Specimen Collection 5 Biopsy 5 poly ICLC 4 binimetinib 4 Therapeutics 4 Psychiatric Rehabilitation 4 sotigalimab 3 montanide ISA 51 3 encorafenib 3 cobimetinib 3 budigalimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Tranexamic Acid × Dermatologic × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡